ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026
The application of excess hazard models for plausible long-term extrapolation in cost-effectiveness: a re-evaluation of immunotherapy in advanced non-small cell lung cancer using the KEYNOTE-024 trial.
Kun Kim et al.PubMed ↗Publisher ↗
No numbers read from the abstract.